Healthcare entity

CPI-818

Product

All 1 tracked stories fall under one category: market-trends. Of the tracked stories, 1 of 1 also mention CPI-006, the most common co-covered peer. Each story carries 2 original sources on average, compared with 2.2 for the broader beat in this window.

Last mentioned: Aug 12, 2026

Entity pulse

Recent coverage · CPI-818

1 story
5 avg impact
0% positive
0% negative
  • 100% neutral

Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.

What the coverage shows about CPI-818

All 1 tracked stories fall under one category: market-trends. Of the tracked stories, 1 of 1 also mention CPI-006, the most common co-covered peer. Each story carries 2 original sources on average, compared with 2.2 for the broader beat in this window. At 5, the average consequence score sits below the same-window beat average of 5.2. CPI-818 appears in 1 tracked Healthcare story from August 12, 2026.

Stories tracked
1
Sources per story
2

Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 40 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.

Coverage cohort

Appears alongside

Other entities that clear the same relevance threshold in stories also covering CPI-818. Shared-story counts are live from our verified record — not editorial picks.

Timeline

  1. Q2 2026 Earnings Release

    Company reported EPS of ($0.19), missing consensus by $0.03.

  2. Ladenburg Thalmann Upgrade

    Ladenburg Thalmann upgraded CRVS to ‘strong-buy’.

  3. Weiss Ratings Upgrade

    Weiss Ratings upgraded Corvus from ‘sell (e+)’ to ‘sell (d-)’.

  4. Director Insider Purchase

    Director David Scott Moore acquired 21,700 shares at $11.53 per share, totaling $250,201.

  5. Wall Street Zen Downgrade

    Wall Street Zen downgraded CRVS from ‘hold’ to ‘sell’.

  6. Goldman Sachs Initiates Coverage

    Goldman Sachs issued a ‘buy’ rating and a $40.00 target price for Corvus Pharmaceuticals.

Stories mentioning CPI-818 1

CPI-818 is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.

See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.